# Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

> **NCT05866510** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 47 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Utidelone and anlotinib

## Key facts

- **NCT ID:** NCT05866510
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-15
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2023-05-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866510, "Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05866510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*